Novo’s next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Summary
Novo Nordisk has shared late-stage trial data for its experimental CagriSema injection. The findings indicate that the new treatment can achieve greater weight reduction than the company's existing obesity medication, Wegovy.
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
Source: Read the full story at US Top News and Analysis
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.